Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while reducing its price target from $82 to $74. The firm stated that the ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $53.19, marking a -1.45% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.14%. At ...

According to Benzinga Pro, CRISPR Therapeutics AG's peer group average for short interest as a percentage of float is 14.28%, ...

Earlier in the week, ARK purchased 10,353 shares of CRISPR on Wednesday, valued at $584,530, and 43,333 shares on Tuesday, totaling $2,509,414. This consistent buying pattern suggests a strong ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...

It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 3.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

In summary, Cathie Wood’s ARK ETF made several significant trades today, including a notable reduction in Tesla holdings and strategic investments in Oklo and Rocket Lab. These moves reflect ARK’s ...